CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of CD19+ Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Listed as NCT05105867, this EARLY_PHASE1 trial focuses on Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and Relapsed or Refractory B-cell Non-hodgkin Lymphoma and remains ongoing. Sponsored by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Unknown EARLY_PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
▶ Show 2 earlier versions
-
May 2022 — Jun 2023 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2021 — May 2022 [monthly]
Recruiting EARLY_PHASE1
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Kunming Hope of Health Hospital
For direct contact, visit the study record on ClinicalTrials.gov .